Vaccination against clinical Mycobacterium tuberculosis isolates
Hybrid 56 (H56) is a new vaccine candidate against pulmonary tuberculosis (TB) developed by Staten Serum Institut (SSI) and currently being tested in clinical trial phase IIa. The vaccine consists of three mycobacterial proteins ESAT-6, Ag85B, and Rv2660c that are fused together in a poly-protein. When formulated in a cationic adjuvant (CAF01), Hybrid56 has shown consistent protective efficacy in